All In Biotech

Drug Trial Radar · NCT07655804

Subcutaneous Calcitonin in Acute Herpes Zoster

The Prophylactic Value of Subcutaneous Calcitonin in Acute Herpes Zoster Patients: A Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

168

Planned (sponsor's estimate)

Start

Jul 1, 2026

Primary completion

Apr 1, 2027

Study completion Oct 1, 2027

Sponsor

Lead sponsor
Tanta UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective randomized controlled study will be conducted to evaluate the effect of adding calcitonin to the standard treatment protocol in patients with acute herpes zoster infection.

Conditions

  • Calcitonin
  • Subcutaneous
  • Acute Herpes Zoster

Interventions

  • CalcitoninDrug

    patients will receive subcutaneous salmon calcitonin 100 IU (ampoule = 1 ml) daily for three weeks

  • SalineOther

    patients will receive subcutaneous saline (1 ml) daily for three weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of postherpetic neuralgia at 3 months after rash onset.Time frame: 3 months after onset of acute herpes zoster rash.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tanta University Hospitals

    Tanta, Gharbia Governorate, Egypt · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.